Trial Profile
A phase I/II study of Pazopanib and weekly Topotecan in patients with platinum-resistant or intermediate-sensitive recurrent ovarian cancer
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 18 Aug 2023
Price :
$35
*
At a glance
- Drugs Pazopanib (Primary) ; Topotecan (Primary)
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions; Biomarker; Therapeutic Use
- Acronyms TOPAZ
- 01 Aug 2023 Results (n=61) assessing safety and efficacy of the combination of Topotecan with Pazopanib in platinum-resistant or intermediate-sensitive recurrent ovarian cancer published in the Journal of Cancer Research and Clinical Oncology
- 26 Sep 2018 This trial has been completed in Germany.
- 05 Jun 2018 Results presented at the 54th Annual Meeting of the American Society of Clinical Oncology